Ataraxis AI and Unicancer Partner to Validate Ataraxis™ Breast Prognostic tool using Global Phase III Trial Data

This partnership will validate the Ataraxis Breast platform using multi-modal data from randomized phase III trials led by Unicancer, initially focusing on hormone receptor–positive (HR+) breast cancer, where recurrence risk assessment and adjuvant treatment decisions remain difficult. Retrospective analyses of data from 1,100+ patients will generate clinical evidence and scientific insight into how AI can improve outcome prediction and treatment-effect estimation.